Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Capital Employed (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Return on Capital Employed data on record, last reported at 1.12% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 93.0% year-over-year to 1.12%; the TTM value through Sep 2025 reached 1.12%, down 93.0%, while the annual FY2024 figure was 1.62%, 193.0% down from the prior year.
  • Return on Capital Employed reached 1.12% in Q3 2025 per NWBO's latest filing, down from 1.18% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 6.51% in Q2 2023 and bottomed at 2.34% in Q3 2023.
  • Average Return on Capital Employed over 5 years is 1.63%, with a median of 1.18% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: soared 556bps in 2023, then crashed -427bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.19% in 2021, then skyrocketed by 270bps to 0.71% in 2022, then skyrocketed by 404bps to 3.58% in 2023, then crashed by -54bps to 1.65% in 2024, then plummeted by -32bps to 1.12% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 1.12% in Q3 2025, 1.18% in Q2 2025, and 1.22% in Q1 2025.